Key Takeaways An already approved drug might help kids with a rare bone cancerPazopanib extended survival in a small group of ...
Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found ...
The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...